Posted by Michael Wonder on 11 Jul 2023
Express Scripts adds three biosimilars to largest formulary to promote competition and advance affordability, choices for patients
11 July 2023 - Express Scripts will include Cyltezo and both Sandoz products (Hyrimoz and unbranded adalimumab-adaz) – inflammatory disease biosimilars with competitive net costs – as preferred products on the National Preferred Formulary alongside Humira.
Express Scripts announced today that as part of its commitment to driving greater affordability for clients and people living with inflammatory conditions, it will add three additional biosimilars to its National Preferred Formulary.
